GI Innovation
Financials
Valuation Metrics
GI Innovation's Market Cap is ₩4387B. At end of 2025 it was ₩1.1T. Ranked #484 of 2,405 in KR market (top 20%), #179 of 1,627 on KOSDAQ (top 11%), #53 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 438.71B KRW | KR#484/2,405 Sec#53/231 |
| Revenue | 5.50B KRW | KR#2,320/2,405 Sec#192/231 |
| Net Income | -39.14B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 105.53B KRW | KR#1,735/2,405 Sec#137/231 |
| Net Assets | 96.64B KRW | KR#1,442/2,405 Sec#113/231 |
| Employees | 84 | KR#1,774/2,405 Sec#145/231 |
| Value | ||
| P/B | 4.54x | KR#2,235/2,405 Sec#193/231 |
| P/S | 79.77x | KR#2,374/2,405 Sec#208/231 |
| FCF Yield | -9.04% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -40.50% | KR#2,233/2,405 Sec#189/231 |
| ROA | -37.09% | KR#2,327/2,405 Sec#209/231 |
| Op. Margin | -812.10% | KR#2,361/2,405 Sec#212/231 |
| Revenue Growth | 1526.80% | KR#3/2,405 Sec#2/231 |
| Financial Health | ||
| Debt Ratio | 9.20% | KR#118/2,405 Sec#26/231 |
| Total Debt | 1.32B KRW | KR#1,929/2,405 Sec#186/231 |
| FCF | -39.68B KRW | KR#2,025/2,405 Sec#200/231 |
| Cash | 29.02B KRW | KR#1,030/2,405 Sec#71/231 |
| Current Ratio | 6.18x | KR#204/2,405 Sec#40/231 |
| Performance | ||
| 1Y Return | -54.97% | KR#2,106/2,405 Sec#193/231 |
| 1M Return | -22.90% | KR#2,006/2,405 Sec#198/231 |
| From 52W High | -67.54% | KR#1,983/2,405 Sec#167/231 |
| 1Y MDD | -67.80% | KR#1,849/2,405 Sec#156/231 |
| Trading | ||
| Volume | 211,602 shares | KR#352/2,405 Sec#29/231 |
| Trading Value | 1.42B KRW | KR#500/2,405 Sec#49/231 |
| Foreign Own. | 8.85% | KR#516/2,405 Sec#44/231 |
| Per Share | ||
| EPS | -607 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,498 KRW | KR#2,198/2,405 Sec#192/231 |
Company Info
GI Innovation, established in 2017, is a specialized fusion protein-based new drug research and development company that listed on KOSDAQ under special provisions in 2023. It boasts a diverse pipeline of immune therapeutics, including immuno-oncology drugs and allergy treatments, facilitated by its GI-SMART platform technology for one-stop early discovery. The company has completed technology transfers to Simcere and Yuhan Corporation and entered into a joint clinical trial agreement with MSD, contributing to the creation of a global innovative new drug pipeline. GI Innovation is headquartered in Songpa-gu, Seoul.